Biotech Showcase Interviews
GigaGen seeks partners for antibody pipelines against 17 IO targets
Using its proprietary Surge platform, GigaGen is able to capture and interrogate natural immune systems rapidly and identify every antibody in circulation against virtually any cancer target. Speaking to Scrip at the Biotech Showcase, CEO David Johnson said he is now seeking partners for 17 distinct IO targets including common checkpoint inhibitors PD-1 and CTLA-4, and more novel targets such as TIM-3 and VISTA.